Member Info for CHELSEA7

Yeah GL both of you, volume just over 1.5m today but there has been just about 110 trades, more than there has been for some time.

Hey welcome to the BB.

On H/L it has been hard to get a live quote for most of the morning,

Volume 352k, 34 trades, spread 1.6%

Catch yer soon, nice start, adrenalin flowing again.................It does make me laugh a non exec sell people say, they know something, but when they buy, it doesn"t mean anything!! Nowt stranger than folk!!!

23P

2 Tick Ups........................22.50/23 +3.41%

22.95 Being Paid..........24p here we come!!

100k at 22.35
180k at 22p

22/22.5 and full askn paid +1.14%

140k volume, first 5 minutes, 22.40 Paid.

Ticking up very soon.

Well that seemed to be a very long weekend indeed and just to remind the last 2 trades on Friday.....................

Date Time Trade Prc Volume Buy/Sell Bid Ask Value
30-Apr-21 17:09:05 22.00 55,000 Unknown* 21.50 22.50 12.10k O
30-Apr-21 16:16:29 22.2811 75,000 Buy*

Looking forward to a very blue week, and seeing us returning to 24p...just or starters

Yeah good find WTP, and we are getting bigger and bigger.

I make that 4 members of the BOD, 4 Non-Executive Directors and 9 members of Senior Management. We have 6 members of the Clinical Advisory Board, (wan"t that set up for the Moditope Trials?) and how many scientists with or without PhDs do we have now?? At first sight it looks like we are very top heavy, but it kinda tells a story. My reasoning for partnership deals is the human resources i.e.Scientists at a Big Pharmas disposal for Research and Development, and beneffiting the Pharma would be a very strong management team at their disposal, so not including non-execs we have 13 members of Senior Management, including them 17 and a further 6 on the clinical Advisory Board, something a doing own at Scancell, lol.

It only seems a very short time ago that we had a total staff of less than a dozen people, and I seem to remember at

my last head count we had 14 scientists, 9 of whom were PhDs. It says a lot about confidence in all our platforms, and there must be a bottle neck of further candidates in Research and Development, that is some wheel of fortune or a Big Pharma to take under their wing with the dedicated staff to have a ready made spin off??

We talk about how quickly sentiment can change on AIM, as receiving news does too, in those sheer numbers of strategic management positions we can see how confident Scancell are and we can see every reason why there will be 3 trials running within months. I would have thought the RNS arriving mid morning on a Friday before a Bank Holiday Weekend was missed by a large proportion of PIs and we saw for those who saw it some very strong buying following Diggles lead in buying 400k more at 20.4p and IMHO I will be very surprised if we don"t break 24p very quickly this week.

By definition 3 trials running in very quick succession opens the door to any number of price inflection news, things are coming together hear me thinks. Night guys catch yer at 7!!!

Ah, there is a link there with the University of Nottingham Sustainable Chemistry Department inked into an RNS on the 7th April 2021. How that concerns Lindy atm I am not sure,

Surprised to see VAL in there. Carry on researching CW

Morning crumbs, yes I have just seen Bermudas post re recruitment for COVIDITY, fair point.

CC, Thanks for that link and another up to date reiteration we could well be on our way to 35p Good to hear.

I see you have mentioned Sanofi in there, there was talk on the grapevine not so long ago that there was a strong possibly tht they would partner Scancell with COVIDITY. i didn"t know they had partnered with Moderna instead, perhaps they found a better deal or Scancell rejected any deal with them and this was about the time when Redmile and Vulpes came forward.
It certainly seemed at that time we were going forward on our own given the alternatives but better deals might well have been offered since. I don"t really buy th fact that to get through Phase 1 is a formality an will increase the IP dramatically enough to justify going alone for now, it i more the point of the complete trial plan and endpoints which i think comes at the beginning o all the said trials. Also one of the biggest hurdle we got a glimpse of was the difficulty we seemed to be having rcruiting any patients for the forthcoming Combo trials. I am still of the opinion that talks of a partnering deal on all platforms are still open and would think news on that will be very well receeived by the market and shareholders alike.

Well thats get to the first news we receive first, to get too 3 trials within months running one after another tells us of the enormity of the work Scancell are doing and getting the approval of all the necessary authorities is a job in itself.

I know for me that when we moved to 27.9 my adrenalin was rushing and almost overnight my portfolio was launched into showing a sizeable profit, and I remember from 12p one after another of us were posting we at last had got ahead of so many averages here it was a great time, and for me I have missed the adrenalin that that period gave me and the choices it gave me to derisk if I wanted too. I remember someone saying to me to get to 40p a share would be much harder but there was not a single one of us whou thought we would move from 4.50 to 27.9 inside that year and the IP has still be rising and would be better reflected in the share price as we get the go ahead for all trials.

Yes I am confident we will get there the journey is a long one and we might never reach the destination but there will be plenty happening in a very short time that just stops me thinking about selling one share now.

Enjoy the weekend guys, the blue skies have given way here in London to a mixed bag of grey clouds which is a shame as I planned to plant myself in the garden and get some colour to my chops but hey summer is coming as sure as news will be very soon. Take care guys.

Crumbs, you were talking about Novavex and Trump, can you only imagine if that was Boris and the allegations from Starmer of sleaze? Doesn"t bare thinking about.

Was just thinking more about the trials running, and whilst waiting for news it is easy to think something might be wrong, for me it was not concern over receiving the news we all want to hear, the issue was not receiving any news at all, nor the twitter line going so quiet.

To add credence to the three trials running and the perspective of something be wrong, what would the odds be that something was wrong with all three platforms, let alone left field news and even the TCRs. Exactly, the odds would be too large to imagine.

Hopefully we will get off to a cracking start on Tuesday morning, I just wonder how many PIs got to hear the news about Diggles purchase from an RNS out at about 11.00 on a Bank Holiday weekend, a very small number I would have thought, so well done all those who bought in just above 20p when it looked like we really needed it.

Afternoon Krafty, commiserations for yesterday, one we had to win, sorry it had to be against you lot.

And good research too cleanerworld, was that really back in 2019? A good reminder to newbies and LTH, yet another platform we all have high hopes for. Thanks.

And our current market cap is £184m, so there is still a huge disparity between so many bios in M/Caps.

Inanaco was very right when he called the SP as "cheap as chips" when we were sub 10p, less than a year ago. In fact a year ago we were 5.15p as a low.

As have said often before I hope now is the time we come up with partnering news on all three trial candidates, SCIB1 has been proven in mono trials, COVIDITY is an offshoot of a proven monotherapy trial, and Moditope, well that is something all LTH have been waiting for for a number of years.

You mention Immunacore and Novavax for now, well which one looks to be vastly undervalued and very soon all the inflection points will be there as we proceed through those Phase 1 trials. Well I am certainly holding strong through a time when our M/Cap should rise expotentially.

Always good to get a press write up and goes some way in quelling fears we hve lost momentum and we are on the radars of many in higher places. What I would give to be a fly on the Scancell walls, whether in the labs or office and of course this is where Martin Diggle has an edge over us PIs.

A good question WTP and a good reply from Ivy. This is a subject matter we have debated for many years, and on those times I have been shot down over my thoughts which i why WTP I say now Diggle is in a far better position, with his position at Scancell to make an informed decision on the right times to buy or as history shows us to sell. Of course that is not suggesting they are going outside the boundaries of inside information, but perhaps it is the definition of inside information that needs looking at at closer inspection. Surely privy I would have thought to company plans and sentiment and even projected cash forecasts he is in a position to decide for himself when the time is right to buy, and would that come under insider information?? Forget non exec directorships we see Director buys every day in all companies, and the same rule applies they all know far more than we do., and the impact of director buys as we saw yesterday was good enough to move the share up 7% and I wonder just how many PIs saw that RNS yesterday\? So I am expecting another move back up north on Tuesday.

Funny old week this has been, I had my second Astra Zeneca jab on Monday and a few of my pals go for those next week, and I guess the same applies for many here. Just to let you know there was no sore arm after a day or two which lasted all week first time, but on top of my norm it really knocked me out all week often sleeping 20 hours, but no feeling of flu or anything else and I noticed since the first jab just how well organised and staffed a local centre had become. So full marks to those responsible for this it was easy, even for me, and I am delighted to have had both jabs now, andmy hope is many more step forward to have theirs done.